ENVISION: UGN-102 and Chemoablation for Low-Grade, Intermediate-Risk NMIBC

Seth Lerner, MD, FACS, Baylor College of Medicine, shares his thoughts on the positive results of the ENVISION trial and the potential for UGN-102 in the treatment paradigm for low-grade, intermediate-risk non-muscle invasive bladder cancer.

Additionally, he expands on the benefits of chemoablative approaches offer to these patients, as well as how chemoablation should be best utilized in the treatment paradigm.